Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAF(V600E/K)- mutated melanoma

PURPOSE: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. EXPERIMENTAL DESIGN: We conducted a phase II trial in melanoma patients whose tumors harbored a BRAF mutation....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Catalanotti, Federica, Solit, David B., Pulitzer, Melissa P., Berger, Michael F., Scott, Sasinya N., Iyriboz, Tunc, Lacouture, Mario E., Panageas, Katherine S., Wolchok, Jedd D., Carvajal, Richard D., Schwartz, Gary K., Rosen, Neal, Chapman, Paul B.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3932005/
https://ncbi.nlm.nih.gov/pubmed/23444215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3476
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares